SunTrust Robinson Humphrey Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces $24 Price Target

SunTrust Robinson Humphrey initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and a $24 price target.

Benzinga · 11/12/2019 11:18

SunTrust Robinson Humphrey initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and a $24 price target.